Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 373

Results For "NAL"

7209 News Found

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant
News | December 08, 2023

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone


Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Drug Approval | December 08, 2023

Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH

Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions


Akums acquires new facility in Baddi to enhance tablet manufacturing capacity
News | December 07, 2023

Akums acquires new facility in Baddi to enhance tablet manufacturing capacity

his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.


Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug
News | December 07, 2023

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya


Venus Remedies gets marketing approvals from Philippines, Saudi Arabia for three drugs
News | December 07, 2023

Venus Remedies gets marketing approvals from Philippines, Saudi Arabia for three drugs

Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana


Granules India received ANDA approval for Sildenafil for oral suspension
Drug Approval | December 06, 2023

Granules India received ANDA approval for Sildenafil for oral suspension

The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million


Briefs: Shelter Pharma and GMM Pfaudler
News | December 06, 2023

Briefs: Shelter Pharma and GMM Pfaudler

GMM Pfaudler US completes acquisition of MixPro


PerkinElmer acquires Covaris to create an innovation-led diagnostics platform
News | December 05, 2023

PerkinElmer acquires Covaris to create an innovation-led diagnostics platform

Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis


Cupid acquires land parcel near Mumbai
News | December 05, 2023

Cupid acquires land parcel near Mumbai

The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output


AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes
News | December 05, 2023

AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes

STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme